AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19416525 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Tailored (MT) packet
Number of subjects: 0
Study 19416525 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Re-Tailored (MRT) packets
Number of subjects: 0
Study 19416525 — intervention group
Group type: COMPARATOR
Intervention: Nontailored (NT) comparison group
Number of subjects: 0
Study 19418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression and euglycaemia from beta cell allograft
Number of subjects: 141
Study 19418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged euglycaemia plus anti-rejection immunosuppressive therapy
Number of subjects: 141
Study 19418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective venous sampling
Number of subjects: 141
Study 19418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine stimulation tests
Number of subjects: 141
Study 19419474 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod applied three to seven times per week for 16 weeks
Number of subjects: 16
Study 19419546 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD disease risk index assessment
Number of subjects: 0
Study 19419611 — intervention group
Group type: EXPERIMENTAL
Intervention: Transantral balloon dilation under local anesthesia
Number of subjects: 30
Study 19419830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast dynamic gadolinium-enhanced MR imaging combined with MR colonography
Number of subjects: 14
Study 19419830 — intervention group
Group type: EXPERIMENTAL
Intervention: MR colonography
Number of subjects: 14
Study 19419830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast dynamic gadolinium-enhanced MR imaging
Number of subjects: 14
Study 19421322 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 13 weeks
Number of subjects: 10
Study 19422756 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted acupuncture (points specific to symptoms) for hypomania over 12 weeks
Number of subjects: 46
Study 19422756 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted acupuncture for depression over 8 weeks
Number of subjects: 46
Study 19422756 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture points off the acupuncture meridian for hypomania over 12 weeks
Number of subjects: 46
Study 19422756 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture for nonpsychiatric health concerns for depression over 8 weeks
Number of subjects: 46
Study 19423725 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI) and antithymocyte globulin (ATG)
Number of subjects: 111
Study 19426530 — intervention group
Group type: EXPERIMENTAL
Intervention: Bluetooth enabled blood glucose monitor
Number of subjects: 0
Study 19426530 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes intensification management program by the Home Care team supported by Bluetooth enabled glucose meters
Number of subjects: 0
Study 19426959 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof Natural IOLs
Number of subjects: 58
Study 19426959 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear IOLs
Number of subjects: 58
Study 19427025 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd-line topotecan-based chemotherapy
Number of subjects: 525
Study 19427617 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 631
Study 19427617 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 631
Study 19427760 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-based substitution fluid
Number of subjects: 29
Study 19427760 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate-based CVVH
Number of subjects: 29
Study 19427992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab
Number of subjects: 96
Study 19432972 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/day)
Number of subjects: 18
Study 19433856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 11
Study 19434385 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0
Study 19434385 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (UUI subgroup)
Number of subjects: 0
Study 19439093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezatiostat hydrochloride liposomes for injection (IV) at 5 dose levels (50, 100, 200, 400, and 600 mg/m2) on days 1 to 5 of a 14-day cycle
Number of subjects: 54
Study 19439093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezatiostat hydrochloride liposomes for injection (IV) at 600 mg/m2 on days 1 to 5 or days 1 to 3 of a 21-day treatment cycle
Number of subjects: 54
Study 19439093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezatiostat hydrochloride liposomes for injection
Number of subjects: 54
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/d
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d (smokers)
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/d (smokers)
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d (smokers)
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d (nonsmokers)
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/d (nonsmokers)
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d (nonsmokers)
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d (African Americans)
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d (Whites)
Number of subjects: 380
Study 19440083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (overall)
Number of subjects: 380
Study 19440247 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 42
Study 19441600 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Self-Management Questionnaire (ASMQ)
Number of subjects: 256
Study 19441600 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Self-Management Questionnaire (ASMQ) after 12 months
Number of subjects: 256
Study 19442962 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 2
Study 19443656 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy with peripheral blood-derived virus-specific cytotoxic T lymphocytes (CTLs) expanded from CB T cells.
Number of subjects: 0
Study 19443656 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLs from CB targeting EBV, CMV, and Adv.
Number of subjects: 0
Study 19443658 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM-AF10 fusion protein
Number of subjects: 0
Study 19443658 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukemia patients harboring CALM-AF10 fusion
Number of subjects: 0
Study 19445710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thyroid fine-needle aspiration biopsies (USG-FNA)
Number of subjects: 268
Study 19445710 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided thyroid fine-needle aspiration biopsies (P-FNA)
Number of subjects: 268
Study 19445710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness comparison
Number of subjects: 268
Study 19446146 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-528 0.3, 1.0, 3.0, or 9.0 mg/kg administered intravenously
Number of subjects: 53
Study 19446146 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-528 0.3, 1.0, 3.0, or 9.0 mg/kg administered subcutaneously
Number of subjects: 53
Study 19446146 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-528 administered intravenously
Number of subjects: 53
Study 19446146 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-528 administered subcutaneously
Number of subjects: 53
Study 19446146 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-528 3.0 mg/kg administered intravenously
Number of subjects: 53
Study 19447923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 224
Study 19448188 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging studies of frontostriatal circuits in children with Tourette's syndrome
Number of subjects: 0
Study 19448188 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging studies of frontostriatal circuits in children with OCD
Number of subjects: 0
Study 19448188 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging studies of adolescents and adults with anorexia nervosa
Number of subjects: 0
Study 19448188 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging studies of adolescents and adults with bulimia nervosa
Number of subjects: 0
Study 19448188 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired capacity for self-regulatory control
Number of subjects: 0
Study 19450141 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program for 6 months
Number of subjects: 165
Study 19450141 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 165
Study 19451441 — intervention group
Group type: EXPERIMENTAL
Intervention: Veltuzumab (80 to 750 mg/m², four once-weekly doses)
Number of subjects: 82
Study 19451441 — intervention group
Group type: EXPERIMENTAL
Intervention: Veltuzumab in follicular lymphoma
Number of subjects: 82
Study 19451441 — intervention group
Group type: EXPERIMENTAL
Intervention: Veltuzumab in marginal zone lymphoma
Number of subjects: 82
Study 19451441 — intervention group
Group type: EXPERIMENTAL
Intervention: Veltuzumab in diffuse large B-cell lymphoma
Number of subjects: 82
Study 19451441 — intervention group
Group type: EXPERIMENTAL
Intervention: Veltuzumab pharmacodynamics
Number of subjects: 82
Study 19451441 — intervention group
Group type: EXPERIMENTAL
Intervention: Veltuzumab pharmacokinetics
Number of subjects: 82
Study 19453788 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 9265
Study 19453788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9265
Study 19454532 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (0.3 mg/kg/day for 4 days)
Number of subjects: 13
Study 19455012 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 0
Study 19455012 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 19455012 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected participants vs. controls
Number of subjects: 0
Study 19456296 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit program implemented after February 16, 2007
Number of subjects: 180
Study 19456296 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitor use
Number of subjects: 180
Study 19456296 — intervention group
Group type: COMPARATOR
Intervention: Control group (before audit program)
Number of subjects: 180
Study 19457240 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DrotAA) administered within 24 hours of first sepsis-induced organ dysfunction
Number of subjects: 305
Study 19457240 — intervention group
Group type: COMPARATOR
Intervention: Drotrecogin alfa (activated) (DrotAA) administered after 24 hours of first sepsis-induced organ dysfunction
Number of subjects: 305
Study 19457245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with CPT-11, 5-FU, and LV for 12 weeks (preoperative phase)
Number of subjects: 35
Study 19457245 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment with the same regimen (CPT-11, 5-FU, and LV) for 12 weeks
Number of subjects: 35
Study 19457245 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 35
Study 19457253 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab alone (21 patients)
Number of subjects: 27
Study 19457253 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab with autologous dendritic cells (6 patients)
Number of subjects: 27
Study 19457253 — intervention group
Group type: COMPARATOR
Intervention: Control (before administration of tremelimumab)
Number of subjects: 27
Study 19457253 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with inflammatory and autoimmune toxicities
Number of subjects: 27
Study 19458012 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (Whe-meal)
Number of subjects: 12
Study 19458012 — intervention group
Group type: COMPARATOR
Intervention: Casein (Cas-meal)
Number of subjects: 12
Study 19458012 — intervention group
Group type: COMPARATOR
Intervention: Cod protein (Cod-meal)
Number of subjects: 12
Study 19458012 — intervention group
Group type: COMPARATOR
Intervention: Gluten (Glu-meal)
Number of subjects: 12
Study 19458352 — intervention group
Group type: COMPARATOR
Intervention: HLA-DQB1 locus
Number of subjects: 2072
Study 19458352 — intervention group
Group type: COMPARATOR
Intervention: IL12A locus (rs6441286)
Number of subjects: 2072
Study 19458352 — intervention group
Group type: COMPARATOR
Intervention: IL12A locus (rs574808)
Number of subjects: 2072
Study 19458352 — intervention group
Group type: COMPARATOR
Intervention: IL12RB2 locus (rs3790567)
Number of subjects: 2072
Study 19458352 — intervention group
Group type: COMPARATOR
Intervention: Five-allele haplotype in the 3' flank of IL12A
Number of subjects: 2072
Study 19458352 — intervention group
Group type: COMPARATOR
Intervention: SNPs at the STAT4 locus
Number of subjects: 2072
Study 19458352 — intervention group
Group type: COMPARATOR
Intervention: SNPs at the CTLA4 locus
Number of subjects: 2072
Study 19459850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with three peptides (TTK, LY6K, IMP-3) at 1 mg each, administered intradermally with 1 mL of incomplete Freund's adjuvant weekly for 5 weeks
Number of subjects: 10
Study 19459850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with three peptides (TTK, LY6K, IMP-3)
Number of subjects: 10
Study 19461827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bion microstimulator
Number of subjects: 9
Study 19463408 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella 2.5 system
Number of subjects: 20
Study 19463409 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 200
Study 19463409 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (historical control)
Number of subjects: 200
Study 19463432 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté paclitaxel-eluting stent
Number of subjects: 1529
Study 19463441 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer-coated sirolimus-eluting stent (Excel) with 6-month dual antiplatelet therapy
Number of subjects: 2077
Study 19464409 — intervention group
Group type: EXPERIMENTAL
Intervention: Linking inpatient clinical registry data to Medicare claims data
Number of subjects: 39539
Study 19464412 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 48612
Study 19466962 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times weekly for up to 16 weeks
Number of subjects: 50
Study 19466962 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 50
Study 19467341 — intervention group
Group type: EXPERIMENTAL
Intervention: F/S bid plus Zileuton 600 mg qid
Number of subjects: 22
Study 19467341 — intervention group
Group type: COMPARATOR
Intervention: F/S bid
Number of subjects: 22
Study 19470620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (titrated from 30 mg twice daily to 90 mg four times daily during a titration phase of 2-16 weeks)
Number of subjects: 17
Study 19470620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 17
Study 19470631 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole, 1 mg, daily for 6 months
Number of subjects: 42
Study 19470888 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 99
Study 19470888 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein
Number of subjects: 99
Study 19471019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 30 mg/day once daily (days 1-21 every 28 days)
Number of subjects: 222
Study 19474140 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum alpha-carotene concentrations
Number of subjects: 5450
Study 19474140 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline lycopene concentrations
Number of subjects: 5450
Study 19474140 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measurements of alpha-carotene and beta-carotene
Number of subjects: 5450
Study 19474140 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-tocopherol
Number of subjects: 5450
Study 19479077 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment at maintenance dose
Number of subjects: 22
Study 19479077 — intervention group
Group type: COMPARATOR
Intervention: GH withdrawal
Number of subjects: 22
Study 19479077 — intervention group
Group type: EXPERIMENTAL
Intervention: GH resumption after withdrawal
Number of subjects: 22
Study 19479315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest Tc-99m-mibi gated-SPECT
Number of subjects: 40
Study 19479315 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) Tc-99m-mibi gated-SPECT
Number of subjects: 40
Study 19479315 — intervention group
Group type: COMPARATOR
Intervention: Control (no LDD)
Number of subjects: 40
Study 19483644 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA: 154-163 (155L) vaccination with Montanide ISA-51, 1 mg, given subcutaneously 7 times on weeks 0, 2, 4, 6, 10, 14, and 18.
Number of subjects: 5
Study 19485285 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1 adrenergic blocker (A1AB) use
Number of subjects: 500
Study 19485285 — intervention group
Group type: COMPARATOR
Intervention: Pseudoexfoliation
Number of subjects: 500
Study 19485285 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus
Number of subjects: 500
Study 19485285 — intervention group
Group type: COMPARATOR
Intervention: Hypertension
Number of subjects: 500
Study 19485285 — intervention group
Group type: COMPARATOR
Intervention: Male gender
Number of subjects: 500
Study 19486718 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score combining complete blood count and basic metabolic profile components
Number of subjects: 71921
Study 19488737 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia clamp study (glucose at 11 mmol/l)
Number of subjects: 24
Study 19488737 — intervention group
Group type: COMPARATOR
Intervention: Control tissues (liver and kidney)
Number of subjects: 24
Study 19488737 — intervention group
Group type: COMPARATOR
Intervention: Comparison between diabetic patients and normal volunteers
Number of subjects: 24
Study 19491229 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSAs) for 12 months
Number of subjects: 112
Study 19492578 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year lifestyle intervention
Number of subjects: 319
Study 19492578 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 319
Study 19492578 — intervention group
Group type: COMPARATOR
Intervention: Control group (52 lean children)
Number of subjects: 319
Study 19492578 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss due to lifestyle intervention
Number of subjects: 319
Study 19492661 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick testing (SPT)
Number of subjects: 1456
Study 19492661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal skin testing (ST)
Number of subjects: 1456
Study 19492661 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.2 mL of a 1:1,000 dilution) intramuscularly
Number of subjects: 1456
Study 19493369 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram up to 60 mg/day for up to 14 weeks
Number of subjects: 2876
Study 19494218 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant interleukin-1-receptor antagonist)
Number of subjects: 9
Study 19496252 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium
Number of subjects: 0
Study 19496252 — intervention group
Group type: COMPARATOR
Intervention: Inhaled methacholine
Number of subjects: 0
Study 19496761 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with muscle relaxation
Number of subjects: 11101
Study 19497063 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 1
Study 19497063 — intervention group
Group type: COMPARATOR
Intervention: Treatment options reviewed
Number of subjects: 1
Study 19498019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib once weekly (0.7-1.6 mg/m²; days 1, 8, 15, and 22; 35-day cycles)
Number of subjects: 31
Study 19498019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib twice weekly (0.7-1.3 mg/m²; days 1, 4, 8, and 11; 21-day cycles)
Number of subjects: 31
Study 19498019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both once-weekly and twice-weekly bortezomib
Number of subjects: 31
Study 19502624 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular obstruction detectable at 1 week
Number of subjects: 42
Study 19502624 — intervention group
Group type: COMPARATOR
Intervention: No detectable microvascular obstruction at any time point
Number of subjects: 42
Study 19502624 — intervention group
Group type: COMPARATOR
Intervention: Microvascular obstruction detectable only at 2 days
Number of subjects: 42
Study 19502624 — intervention group
Group type: COMPARATOR
Intervention: Microvascular obstruction detectable at both 2 days and 1 week
Number of subjects: 42
Study 19502645 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt revascularization with intensive medical therapy
Number of subjects: 2368
Study 19502645 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 2368
Study 19502645 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitization therapy
Number of subjects: 2368
Study 19502645 — intervention group
Group type: COMPARATOR
Intervention: Insulin-provision therapy
Number of subjects: 2368